954239-03-3

Usage

Uses

Used in Pharmaceutical Industry:
(2-AMINO-5-TRIFLUOROMETHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as a key intermediate in the synthesis of various pharmaceuticals for its potential to interact with biological targets and contribute to the development of new drugs.
Used in Agrochemical Industry:
(2-AMINO-5-TRIFLUOROMETHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is used as a building block in the creation of agrochemicals, leveraging its stability and reactivity properties to produce compounds that can be applied in agricultural settings.
Used in Medicinal Chemistry Research:
(2-AMINO-5-TRIFLUOROMETHYL-PHENYL)-CARBAMIC ACID TERT-BUTYL ESTER is utilized as a valuable tool in medicinal chemistry for exploring its interactions with biological targets and its potential applications in the design of new therapeutic agents.

Upstream product

• 402-14-2 2-nitro-5-(trifluoromethyl)aniline 
• 24424-99-5 di-tert-butyl dicarbonate 

Relevant academic research and scientific papers

HDAC3-SELECTIVE INHIBITORS

Disclosed herein are selective HDAC inhibitors. In some embodiments, the compounds are selective HDAC3 inhibitors. The compounds are useful to treat a variety of conditions, including cancers, i.e., breast cancer, cachexia, and liver steatosis.

Targeting breast cancer stem cells by novel HDAC3-selective inhibitors

Although histone deacetylase (HDAC) inhibitors have been known to suppress the cancer stem cell (CSC) population in multiple types of cancer cells, it remains unclear which HDAC isoforms and corresponding mechanisms contribute to this anti-CSC activity. Pursuant to our previous finding that HDAC8 regulates CSCs in triple-negative breast cancer (TNBC) cells by targeting Notch1 stability, we investigated related pathways and found HDAC3 to be mechanistically linked to CSC homeostasis by increasing β-catenin expression through the Akt/GSK3β pathway. Accordingly, we used a pan-HDAC inhibitor, AR-42 (1), as a scaffold to develop HDAC3-selective inhibitors, obtaining the proof-of-concept with 18 and 28. These two derivatives exhibited high potency and isoform selectivity in HDAC3 inhibition. Equally important, they showed in vitro and/or in vivo efficacy in suppressing the CSC subpopulation of TNBC cells via the downregulation of β-catenin.